Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Repurposing a Drug Used for Alcohol Abuse May Overcome MM Treatment Resistance
According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
Researchers Call for Push to More Holistic, Collaborative Care for Young Adults With T1D
The group noted that this transformation should affect changes at every level, including at the individual level during patient visits, at the organization level in how clinical encounters are organized, and at the national level in both policies and guidelines for type 1 diabetes (T1D).
Pressure-Induced Increase in PD-L1 Expression May Dull Effect of CAR T-Cell Therapy
The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also suggest that adding PD-1/PD-L1 inhibitors to CAR T-cell therapy could help address this.
Levels of Certain Thyroid Hormone May Help With Risk Stratification in MM
With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
Poorer Outcomes Associated With Recurrent aGVHD Warrant Independent Recognition, Says Study
After a median follow-up of 535 days, analysis showed that recurrent acute graft-versus-host disease (RaGVHD) carried several implications for survival, leading the researchers to call for further risk stratification of aGVHD.
Study Gives Insight Into Fidaxomicin’s Gut-Sparing Activity in Clostridioides difficile
Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.
Study Finds Risk of Overinvestigation in Patients With Lung Cancer Not Fit for Anticancer Treatment
Among a group of patients with lung cancer who were not suitable for anticancer treatment, the researchers found that 40% underwent additional investigations after their initial CT scan before eventually receiving best supportive care.
Study: Effective Treatment Significantly Improves HRQoL in Recurrent Clostridioides difficile
The researchers wrote that their findings showcase the need for close monitoring of patients and for effective treatments for those with recurrent infection, which occurs in 15%-30% of all patients with Clostridioides difficile.
MoCA Scores in HD Correlate With Caudate Atrophy, Cortical Thinning, Says New Research
The findings suggest that the tool can be used to not only assess cognitive impairment in Huntington disease (HD) but also to detect brain atrophy patterns associated with cognitive status in these patients.
New Study Details Frequency of SDOH Documentation Among Patients With Lung Cancer
A decade’s worth of data included more than 5 million social determinants of health (SDOH) attributes across nearly 2 million clinical notes from the patient visits extrapolated from a natural language processing system.
Pretreatment PROs May Have Survival Implications in DLBCL, Finds Exploratory Study
The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.
European Study Shows High Rate of Skin Conditions, Diseases
When including patients who had a mole check or cancer screening, the proportion of patients with at least 1 dermatological condition or disease increased to 47%; both non-melanoma and melanoma skin cancers were among the top 12 skin diseases reported in the study.